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1 Introduction 
1.1 Renal cell carcinoma 
Renal cell carcinoma (RCC) is the fifth most common cancer in Europe (Ferlay et al. 2018). 
In 2019 more than 73,000 new cases and 14,000 deaths were estimated in the United States 
of America (Siegel et al. 2019). RCC is a heterogeneous disease; 75% of RCC are of clear cell 
histology, 5% are papillary (each for type 1 and type 2 disease), the rest chromophobe, 
oncocytoma or other rare histologic types (Muglia and Prando 2015). RCC is also 
heterogenous at the molecular level and each histologic type of the disease corresponds to a 
different cluster of underlying mutations. The majority of RCC present as sporadic disease 
(not due to germline mutations). An estimated 5-10% of RCC are manifestations of inherited 
diseases. There are several familial cancer syndromes caused by germ line mutations of 
different genes associated with RCC. It is important to identify patients with inherited tumor 
syndromes because the resulting patient surveillance can lead to early diagnosis of RCC and 
thus a better outcome. In addition, genetic and biochemical studies that gain insight into the 
mechanism of inherited diseases predisposing to RCC do inform the abnormalities 
underlying the sporadic tumors and therefore can lead to the design of rational treatments 
(Schmidt and Linehan 2016). This thesis studies two different inherited cancer syndromes 
Birt-Hogg-Dubé (BHD) and von Hippel-Lindau (VHL) disease, looking for a better 
understanding of the genetics and pathways dysregulated in these diseases. The work 
presented in this thesis is part of bigger projects established in the Iliopoulos Laboratory at 
Massachusetts General Hospital and Harvard Medical School. 
1.2 Birt-Hogg-Dubé syndrome 
The BHD syndrome was first described in 1977 by Arthur R. Birt, Georgina R. Hogg and 
William J. Dubé as “Hereditary fibrofolliculomas with trichodiscomas and acrochordons”. 
In 2002 the syndrome was linked to a germline mutation of the tumor suppressor gene 
folliculin (FLCN) (Nickerson et al. 2002). Patients are characterized by developing benign skin 
lesions (fibrofolliculomas or trichodiscomas), spontaneous pneumothoraxes caused by lung 
cysts and the development of renal cell carcinomas. 
The discovery of FLCN mutations as the cause of BHD disease provides the opportunity to 
test patients for germline mutations. Most BHD patients develop multiple RCC lesions 
during their lifetime. Those can be treated and cured by surgery if detected at early stage. The 
challenge is to preserve normal renal parenchyma, and therefore protect kidney function 
despite repeated procedures to remove RCC. Early and regular abdominal imaging allows 
the detection of RCC lesions when they are still small. At this stage, the lesions can be 
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removed through surgeries, taking away the least kidney parenchyma possible (nephron-
sparing surgery). BHD diagnosis through genetic testing and regular patient surveillance 
allows to detect local lesions early which is crucial for kidney preservation and patient 
outcome (Stamatakis et al. 2013). Regular abdominal imaging of BHD patients was 
recommended to start at the age of 20 (Jensen et al. 2017), a concept that is now challenged 
by an early onset BHD case report presented in my thesis. 
Patients with BHD disease are at a lifetime risk of developing RCC (of variable histology), 
pneumothorax, lung cysts, and fibrofolliculomas or trichodiscomas of the skin. The type of 
BHD-associated lesions, their age of onset and their overall severity differs from patient to 
patient. Patients that develop spontaneous pneumothorax and/or fibrofolliculomas should 
be referred for genetic counseling and testing of germline BHD mutations. Algorithms for 
BHD diagnosis are still developing and improving continuously based on patient data. 
1.2.1 The tumor suppressor protein folliculin 
Nickerson et alii (et al.; 2002) cloned the FLCN tumor suppressor gene by linkage analysis 
of BHD families. FLCN localizes to chromosome 17p11.2 and encodes the 64kDa FLCN 
protein. The gene was named after the benign skin lesions of BHD patients, 
fibrofolliculomas. The FLCN gene consists of 14 exons and spans a 20kB of genomic 
deoxyribonucleic acid (DNA) space. Nickerson et al. reported that the FLCN gene is 
mutated at the germline of affected families. 
Genetic and experimental evidence suggest that FLCN acts as a tumor suppressor gene. 
Most of the mutations predict for a truncated form of FLCN protein or are small intragenic 
deletions, but single base substitutions, duplications, and insertions have also been reported 
(Lim et al. 2010). The second, wild type (WT) allele, of FLCN is inactivated in the BHD-
related RCC by an independent second inactivating mutation or deletion (loss of 
heterozygosity) (Vocke et al. 2005). These findings conform to Knudson’s “two hit 
hypothesis” and suggest that FLCN is a tumor suppressor gene (Knudson 1971). 
The genetic evidence that FLCN acts as a tumor suppressor gene is corroborated 
experimentally, using a mouse xenograft assay. FLCN -/- cells injected into the flanks of 
immunocompromised nude mice grow xenografts whereas the same cells, with WT FLCN 
reintroduced do not form tumors. Laura Laviolette previously used this in vivo assay in the 
Iliopoulos Laboratory (Laviolette et al. 2017). 
Since the identification of FLCN many hypotheses for its function and potential pathways 
regulated by FLCN have been put forward. However, the pathways dysregulated through 
mutations of FLCN leading to the development of BHD disease are still to be determined. 
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Two FLCN interacting proteins (FNIP 1 and 2) have been identified. Both showed binding 
of FLCN through its c-terminus and also interacted with AMP-activated protein kinase 
(AMPK). This interaction suggests a possible role of FLCN in modulating energy and 
nutrient sensing of the cell and might interact with the AMPK/mTOR axis (Baba et al. 2006; 
Hasumi et al. 2008). The mammalian Target of Rapamycin (mTOR) is a serine/threonine 
kinase and part of the multiprotein complex mTOR 1 regulating cell growth, mRNA 
translation, and other oncogenic pathways that are upregulated in many cancers (Guertin and 
Sabatini 2007). This interaction of FLCN has led to clinical trials with mTOR inhibitors for 
BHD associated kidney cancers (Benusiglio et al. 2014). 
However, other findings have indicated that FLCN also plays a role in the activation of 
mTOR complex 1 (mTORC1), by enabling its localization to the lysosomal membrane. Here, 
it binds to heterodimers consisting of RagA or B and RagC or D, depending on their 
nucleotide loading state, which is regulated by upstream sensors (Kim et al. 2008). The 
GTPase heterodimer binds mTORC1 when RagA/B binds guanosine triphosphate (GTP) 
and RagC/D binds guanosine diphosphate (GDP) (Tsun et al. 2013). There are different 
regulators of the nucleotide loading state of the Rag GTPases that ensure mTORC1 activity 
responds to nutrient levels in the cell correctly. 
One of those regulators is the complex of FLCN and FNIP2, which has been identified to 
stimulate GTP hydrolysis of RagC/D to GDP, enabling mTORC1 activation (Petit et al. 
2013; Tsun et al. 2013). Recently the structure of the FCLN/FNIP2 RagA/RagC complex 
has been solved at a 3.6 Angstrom resolution (Lawrence et al. 2019). This complex form 
when the cell is under amino acid starvation, FLCN/FNIP2 then lose the GTPase activating 
function towards RagC/D and mTORC1 is inactive. Lawrence et al. (2019) discovered a 
displacement of a catalytically required arginine (arginine 164) in FLCN leading to the loss 
of this function. In addition, Shen et al. (2019) investigated the structure through 
Figure 1: "Molecular pathways and cellular processes in which FLCN may have a functional role." 
Figure and text from Schmidt and Linehan 2018 with kind permission of Elsevier 
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cryoelectron microscopy analysis (Figure 2a) and identified the same arginine as the catalytic 
arginine finger for the GTPase activating function. 
Shen et al. (2019) also investigated the interaction between FLCN and FNIP2 closer and 
identified that the heterodimer is stabilized through two DENN (differentially expressed in 
neoplastic versus normal cells) domains of the C termini of each protein and two Longin 
domains of the N termini of both proteins. The Longin domain heterodimer localizes 
between both nucleotide binding domains of RagA and Rag C in the complex (Figure 2 a 
and c). This structure was interpreted to be an on-pathway intermediate to GTP hydrolysis 
and further investigation is needed to understand how it translates amino acid signals toward 
Figure 2: "General Architecture of the FLCN-FNIP2-Rag-Ragulator Supercomplex" Figure and 
text from Shen et al. 2019 
a Atomic model, cartoon model, and domain assignment for the FLCN-FNIP2-Rag-Ragulator 
nonamer. Subunits of the FLCN-FNIP2-Rag-Ragulator complex are colored as following: purple, 
FLCN; orange, FNIP2; pink, RagA; cyan, RagC; brown, Ragulator. 
b Domain arrangement for the FLCN-FNIP2-Rag-Ragulator supercomplex. Inter- and intra-
subunit interactions are shown by gray bars between domains. The DENN domain within FNIP2 
is split in two, denoted as DENNn (DENN domain N-terminal fragment) and DENNc (DENN 
domain C-terminal fragment).  
c Structural model for the Longin domain heterodimer within the FLCN-FNIP2 complex.  
d Structural model for the DENN domain heterodimer within the FLCN-FNIP2 complex. With 
kind permission of Cell Press 
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mTORC1. Interestingly, these findings suggest a new FLCN function, that is carried out 
mainly by the N terminal region of the protein. However, most studies so far suggested the 
FLCN c-terminal region as necessary for its function and interestingly, most BHD associated 
FLCN mutations predict for a truncated protein (Lim et al. 2010). 
Other familial cancer syndromes (Table 1) associated with RCC e.g. Von Hippel-Lindau 
(VHL), hereditary papillary renal carcinoma type 1 (HPRC-1), hereditary leiomyomatosis and 
renal cell carcinoma (HLRCC) predispose patients to RCC of one specific histology and are 
not linked to FLCN mutations. VHL is caused by germline mutation of the VHL gene and 
predisposes patients to exclusively clear cell RCC and other hyper vascular tumors. HPRC-
1 is caused by mutations of c-met. HPRC-1 patients predominantly develop type 1 papillary 
renal carcinomas that show papillary or tubulopapillary histologies (Lubensky et al. 1999). 
HLRCC is caused by germline mutations of fumarate hydratase and leads to the development 
of type 2 papillary renal cancers along with cutaneous and uterine leiomyomas (Menko et al. 
2014). 
In contrast to other RCC tumor suppressor genes, FLCN associated RCC can occur as any 
histologic type and even in hybrid forms with features of more than one histological type. 
RCC tumors in BHD patients may be chromophobe, oncocytic, hybrid forms of 
chromophobe with oncocytic, clear cell, papillary or even non-classifiable RCC (Pavlovich 
et al.  2002). Frequencies of the different types vary from study to study but hybrid tumors 
containing chromophobe and oncocytic histological subtypes are among the most frequent 
in BHD. 
Table 1: Familial cancer syndromes 
Familial cancer syndromes 
syndrome Mutated gene Signaling pathway/target RCC subtype 
VHL VHL HIF2a Clear cell type 
BHD FLCN unknown multiple 
HPRC-1 c-met Receptor tyrosine kinase Type 1 papillary 
HLRCC Fumarate hydratase Tricarboxylic acid cycle Type 2 papillary 
 
There are no known phenotype-genotype correlations in BHD disease. Although there have 
been statistical observations of more lung cysts and spontaneous pneumothoraxes in BHD 
patients with exon 9 and 12 mutations (Toro et al. 2008). The type of germline mutation 
seems not to inform about penetrance, expressivity or aggressiveness of the disease. No 
correlation between germline mutations and histologic type of RCC has been identified. Over 
time, as the number of detected FLCN mutations will increase, it is possible that such 
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correlations will be established, and the type of germline mutation will inform the clinical 
course of the disease and therefore shape our strategies for prevention and/or early detection 
of RCC and other BHD-related lesions. 
1.3 Von Hippel-Lindau disease 
In the early 20th century both Eugen von Hippel and Arvid Lindau described patients with 
angiomas (highly vascularized tumors) in the retina and central nervous system (von Hippel 
1904; Lindau 1927). Later it was discovered that these angiomas were caused by a germline 
mutation of the von Hippel-Lindau (VHL) gene located on chromosome 3p25 (McKusick 
and Amberger 1993). The familial disease caused by this mutation along with the gene are 
now named after their first describers, von Hippel and Lindau. 
Patients with a germline mutation in the VHL gene are predisposed to the development of 
highly vascularized benign and malignant tumors throughout their lifetime. The most 
common of these are clear cell renal cell carcinoma (ccRCC), hemangioblastomas of the 
central nervous system including the retina, pheochromocytoma, and paragangliomas, 
neuroendocrine tumors of the pancreas and serous cystadenomas of the middle ear, 
pancreas, epididymis, and adnexal organs. In these tumors the remaining WT VHL allele is 
inactivated by somatic mutation or deletion. In keeping with the Knudson hypothesis, 90% 
of sporadic ccRCC harbor a bi-allelic inactivation of the VHL gene (Cancer Genome Atlas 
Research Network 2013). 
The VHL protein serves as the substrate-binding subunit of an E3 ubiquitin ligase complex 
(Lisztwan et al. 1999). Here, the VHL protein plays an important role in the regulation of 
hypoxia metabolism by binding to the alpha subunits of hypoxia inducible factors 1a or 2a 
(HIF-1a, HIF2a also known as EPAS) and targeting it for proteasomal destruction. At 
normal oxygen concentrations in the cells, prolyl-hydroxylase domain enzymes (PHD 1-3, 
EGLN) mediate the hydroxylation of specific prolyl residues in the HIF-a subunits. These 
prolyl residues are part of an oxygen dependent degradation domain. VHL recognizes 
hydroxylated HIF-a and via the E3 ubiquitin ligase complex promotes ubiquitination, which 
then leads to HIF’s proteasomal degradation (Figure 3a, Lisztwan et al. 1999). 
In hypoxic cells, HIF-a is not hydroxylated and therefore not recognized by VHL. Stabilized 
HIF-a subunits dimerize with the constitutively expressed beta subunits (HIF-1b also 
known as ARNT or HIF2b) and bind to DNA at regions of specific base pair sequence 
termed hypoxia responsive elements (HRE). Dimerization and binding of HIF to HRE leads 
to transactivation of a wide range of genes (Figure 3b, Schödel et al. 2011). Loss-of-function 
mutations of the VHL gene causes constitutive upregulation of HIF-a and constitutive 
activity of hypoxia inducible factors (Iliopoulos et al. 1996). The oxygen-dependent HIF 
regulation fails, and cells appear to be under hypoxia all the time, initiating hypoxic cell 
metabolism and angiogenesis. Constitutive HIF expression promotes tumor growth by 
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turning on several genes that enhance cell proliferation and reshape tumor metabolism 
(Majmundar et al. 2010). 
 
Figure 3: Hypoxia inducible factors in (a) normoxic and (b) hypoxic cells 
(modified after Aki et al. 2018) 
1.3.1 Clear cell renal cell carcinoma and hypoxia metabolism 
Histopathologically, RCC can be separated into different types, the most prevalent being the 
highly vascularized ccRCC (50-75%) (Shuch et al. 2015). As in the familial type of ccRCC 
also 90% of the cases of sporadically occurring tumors are characterized by a loss of function 
of VHL leading to an upregulation of HIFa as stated above (Cancer Genome Atlas Research 
Network 2013). 
There are different isoforms of HIFa that can have both overlapping and distinct functions. 
The most studied isoforms are HIF1a and HIF2a. Interestingly, in ccRCC HIF1a is a 
potential tumor suppressor protein by inhibiting tumor growth (Shen et al. 2011). Contrary 
to that, HIF2a functions as an oncogene in ccRCC and it has been proven necessary and 
sufficient for the development of VHL-null ccRCC (Kondo et al. 2002; Zimmer et al. 2004; 
Iliopoulos et al. 1996). These opposing functions can be accounted for by the different set 
of genes activated by the two HIF paralogs (Schödel et al. 2016). 
Upregulation of HIF2a rewires cancer cell metabolism and activates cancer angiogenesis. 
This enables the tumor cells to grow faster than the surrounding normal cells. Among the 
target genes of HIF are the vascular endothelial growth factor (VEGF) and its receptor, 
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activating angiogenesis. It also has been shown that HIF2a activates the known oncogene 
c-Myc, which promotes tumor proliferation (Gordan et al. 2007). Overall, HIFs play an 
important role in cancer specific cell changes such as angiogenesis, erythropoiesis, cell 
proliferation, metabolism and metastasis (Majmundar et al. 2010). 
Early stage renal cell cancer can be cured by surgery. However, 20-30% of the patients are 
diagnosed at a metastatic stage of the disease and for these patients, therapeutic options are 
limited (Motzer et al. 1996). Efforts for targeted therapies of ccRCC have focused on 
targeting HIF2a or its downstream targets. Drugs inhibiting the product of HIF2a target 
genes, such as the VEGF or its cognate receptors showed promising results. However, 
hypoxia caused by this inhibition again leads to an upregulation of HIFs and other hypoxic 
pathways are activated making these cells resistant to VEGF inhibition (Pichler and 
Heidegger 2017). 
1.3.2 Small molecule HIF2a inhibitors 
The Iliopoulos Laboratory established a cell-based assay to screen for small molecules 
inhibiting HIF2a expression in VHL knock out RCC cells (Zimmer et al. 2008). VHL-null 
cells were stably infected with a luciferase reporter driven by the DNA binding sites of 
HIF2a, called hypoxia responsive elements (HRE, 7H4 cells, Figure 4a). Binding of HIF2a 
to four HREs upstream of the Luciferase coding region drives the translation of Luciferase. 
When stably introduced into VHL-deficient ccRCC cell lines, the Luciferin signal represents 
the overall HIF2a activity in those cells. To control for non-specific suppression of 
transcriptional activity the library was tested on the same cells stably infected with luciferase 
reporter driven by a constitutive, HIF-independent, simian virus 40 (SV40) promoter (7SV40 
cells, Figure 4a). This assay is described further in the methods section. 
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Figure 4: Luciferase reporters and synthesis of Compound 76 
A: Schematic of Luciferase reporters for cell based high-throughput screen of small molecule 
libraries. (Zimmer et al. 2008, with kind permission of Molecular Cell.) B: Two different routes to 
synthesize compound 76 out of commercially available methyl 3-amino-2-thiophene carboxylate (2). 
C: X-ray crystal structure of compound 76. The light blue line represents a hydrogen bonding within 
the molecule. (b and c: Wang et al. 2019, with kind permission of Tetrahedron Letters) 
Using this assay, the Iliopoulos Laboratory performed a high-throughput screen with a total 
amount of 58,000 compounds to identify small molecule HIF2a inhibitors. 8 compounds 
were identified that decrease Luciferase activity in 7H4 cells by more than 80% without 
having an effect on 7SV40 cells. Those findings were then confirmed by testing these 
compounds in different RCC cell lines (Zimmer et al. 2008).  
Electrophoretic mobility shift assays showed that the compounds repressed HIF2a 
translation by enhancing the binding of iron regulatory protein 1 (IRP1) to the HIF2a 
messenger ribonucleic acid (mRNA). The binding region was identified to be an iron 
responsive element (IRE) in the 5’ untranslated region of the HIF2a transcript (Sanchez et 
al. 2007). The HIF1a transcript does not contain this IRE, which makes the compounds 
very specific to HIF2a translation inhibition (Zimmer et al. 2008). 
In vivo studies in a VHL knockout zebrafish model showed significant activity of these HIF2a 
inhibitors. VHL deficient zebrafish show phenotypes similar to these of VHL patients such 
as erythrocytosis and blood vessel overgrowth in the brain and retina, similarly to 
hemangioblastomas in VHL patients. Moreover, epithelial abnormalities in the fish kidney 
resembled characteristics of early stage ccRCC (Noonan et al. 2016). Treatment of vhl -/- 
zebrafish with compound 76 (Figure 4c), the lead compound of the HIF2a inhibitors 
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showed normalization of these pathologies and improved overall survival in early embryonic 
stages (Metelo et al. 2015). 
Taken together, these findings strongly suggest compound 76 inhibits HIF2a translation. 
However, further studies are required to identify how and in what way the compounds 
interact in the cell and what target proteins they bind to or interact with. A cell-based screen 
as done by Zimmer et al. (2008) is a great tool to identify compounds modulating one specific 
phenotype in the cell. However, identification and validation of the target which may be far 
away from the process one is studying is often difficult.  
The derivative compounds presented in this thesis were synthesized by the Laboratory of 
Drug Discovery in Neurodegeneration of the Brigham and Women’s Hospital and Harvard 
Medical School. The synthesis of compound 76 identified by Zimmer et al. was recently 
published by this laboratory (Wang et al. 2019). To allow further studies of the compounds’ 
biological properties as well as the structure activity relation, a facile and scalable synthetic 
route was developed. Two different methods were tested to convert the commercially 
available methyl 3-amino-2-thiophene carboxylate (Figure 4b #2) into compound 76. The 
structure was then confirmed by single crystal X-ray analysis (Figure 4c). This method allows 
the substitution of the substrate with different arylamines to synthetize analogs of compound 
76 for investigation of the structure activity relation (Wang et al. 2019). All newly synthesized 
compounds can be tested by Luciferase assay and their activity can be compared to 
compound 76. 
1.4 Project aims 
Gaining a better understanding of the mechanisms underlying specific hereditary cancers 
may lead to the development of novel therapeutic strategies not only for familial but also for 
sporadic cancers. In this work two different hereditary cancer diseases associated with RCC 
were investigated. 
Early diagnosis and regular surveillance of BHD patients is crucial to reduce morbidity and 
mortality. Investigation of possible genotype-phenotype correlation of BHD disease requires 
identification of FLCN mutations promoting tumor growth in vivo. 
HIF2a is a validated target for treatment of sporadic and inherited ccRCC as well as other 
HIF2a-driven tumors. Small molecular HIF2a inhibitors identified by the Iliopoulos Lab 
show promising characteristics including specificity and efficacy in vitro and in vivo. Further 
preclinical improvement of HIF2a inhibitors depends on identification of the direct target 
of these compounds. In addition, identification of the direct targets may reveal new 
information about HIF regulation and hypoxia sensing. 
My thesis work addresses the following questions: First, can we predict whether a novel 
FLCN mutation leads to loss-of-function and therefore to be tumorigenic in BHD 
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syndrome? We would like to provide proof that a patient derived mutant FLCN can generate 
a tumorigenic phenotype in an RCC xenograft tumor model. 
Second, can the specific target proteins be identified that bind to the small molecules 
generated by high throughput screen? We will approach this question through the following 
three steps: 1. Generation of specific small molecule analogs that are substrates for click 
chemistry and maintain activity. 2. Development and optimization of pull-down techniques 
to purify candidate proteins. 3. Identification of candidate proteins that bind small molecule 
inhibitors. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Reagents and antibodies 
Table 2: Reagents 
Reagents 
Reagent Company 
30% Acrylamide: 0.8 Bis-Acrylamide stock 
solution 
National Diagnostics (#EC-890) 
Amphopac Millipore 
Azide Magnetic Beads Click Chemistry Tools (#CLK-1036) 
Biotin-azide Click Chemistry Tools (#AZ104-25) 
Dulbecco’s phosphate buffered saline 
(DPBS) 
Sigma Aldrich (#D8537) 
Dynabeads M-280 Streptavidin Invitrogen (#11205D) 
Dynabeads Protein A Invitrogen (#10001D) 
FBS (fetal bovine serum) Corning (#35-010-CV) 
Lipofectamine 2000 transfection reagent Invitrogen (#11668019) 




Phosphate Buffered Saline Gibco (#10010023) 
Polybrene Millipore (#TR-1003-G) 
Ponceau S Sigma-Aldrich #P3504 
Precision Plus Protein Kaleidoscope Bio Rad (#1610375) 
Puromycin Sigma-Aldrich (#P8833) 
0.25% Trypsin-EDTA (1X) Gibco (#25200056) 
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Table 3: Antibodies 
Primary Antibodies for Western Blot 
Target Species Company Dilution 
Folliculin rabbit Cell Signaling (#3697) 1:10,000 
Aconitase 1 rabbit Gift of Dr. Kostas Pantopoulos (McGill 
University, Montreal, Canada). 
1:1,000 
Actin mouse Invitrogen (#MA5-11869) 1:30,000 
Peflin rabbit Proteintech (#10151) 1:500 
Secondary Antibody for Western Blot 
Rabbit goat Invitrogen (#G21234) 1:10,000 
Mouse goat Invitrogen (#G21040) 1:10,000 
 
2.1.2 Kits 
Table 4: Kits 
Kits 
Name Company 
Bradford assay system Bio Rad (#5000006) 
Luciferase assay system Promega (#E1910) 
Click it protein reaction buffer Invitrogen (#C10276) 
Click-It Protein Enrichment Kit Invitrogen (#C10416) 




The plasmids and oligonucleotides used to generate FLCN WT were previously described 
(Laviolette 2017). FLCN del pG84-E132 was PCRed in three steps. We designed new oligos 
that included the last 21 bases encoding the 7 amino acids before the glycine, which is the 
first amino acid that is deleted by the mutation (first 21 bases of OI-2399) and then the first 
2 Materials and methods 14 
19 bases that follow directly after the deletion, encoding the amino acids following the 
deleted glutamine 132 in the wildtype FLCN mRNA (last 19 bases of OI-2399). OI-2398 is 
the antisense strand of OI-2399. For all PCRs the Phusion high-fidelity PCR kit (Fisher 
#F553S) was used. 
The first PCR (Figure 5) was to generate the first part of FLCN up to the deletion. Oligos 
used were 5’-GCGC GGATCC GCCACC ATG GAT TAC AAA GAT GAT GAT AAA 
AAT GCC ATC GTG GCT CTC TG-3’ (OI-1468, encoding the Bam HI restriction site, 
the Kozak consensus sequence and the start of the FLCN mRNA) and 5’-C TTC ACG GCC 
AGG GCA GAC CTC GCA CAT GTC CGA CTT TTT-3’ (OI-2398). The second PCR 
(Figure 5)  generates the FLCN part after the deletion, oligos used were 5’-AAA AAG TCG 
GAC ATG TGC GAG GTC TGC CCT GGC CGT GAA G-3’ (OI- 2399) and 5’-GCGC 
GAATTCA GTT CCG AGA CTC CGA GGC TGTG-3’ (OI-613, encoding the end of the 
FLCN mRNA and the Eco RI restriction site). Both PCR results were controlled by running 
them through agarose gels and controlling the product sizes. The correct bands (PCR 1 
260basepairs and PCR2 1390basepairs) were then cut out and eluted with an agarose gel 
extraction kit in 30µL ddH2O. 
 
Figure 5: Schematic of PCRs creating the patients FLCN mutation p.Gly84_Glu-132del as 
insert for a plasmid. 
With the third and last PCR the whole insert for the plasmid is generated using the results of 
the first two PCRs as a template (Figure 5). These results now include the sequence before 
and after the deletion and are partly sense and antisense strands. Oligos OI-1468 and OI-
613 were used again for the beginning and end of the FLCN del pG84-E132 so it can be 
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used as an insert for a pBABE puromycin plasmid. The result was controlled by running a 
sample of the PCR through a 0.8% agarose gel, it had the size of about 1650 base pairs. 
The PCR was then purified using a QIAquick PCR purification kit (Fisher #K310001) and 
eluted in 30µL of ddH2O. Following digestion, the insert was ligated into the pBABE 
puromycin vector with BamHI and EcoRI restrictions sites. The results were confirmed 
through sequencing by the MGH DNA core facility. 
Plasmids used for the Luciferase assay were already established in the lab as described by 
Zimmer et al. (2008). 
2.2.2 Retrovirus production and transduction of cells 
293T cells were transfected with retrovirus constructs and vector using lipofectamine as 
indicated by the products instructions (Invitrogen). 5µg of ampho-pac, VSV-G and plasmid 
DNA was mixed in 1mL of DMEM as well as 37.5µL lipofectamine in a separate tube. After 
5 minutes both tubes were mixed and set for 20 minutes. The mixture was added to the 
plates and after 6-12 hours the medium was changed. 
Virus containing supernatant was harvested 24h after transfection of 293T cells, polybrene 
was added to the supernatant up to a concentration of 4µg/mL and the supernatant was 
filtered through a 0.22µM filter. The filtrate was mixed in a 1:1 ratio with regular DMEM 
and added to 6-well plates of cells that were to be transduced. Plates were sealed and 
centrifuged at 4000RMP for 40 minutes at room temperature. After another 24 hours, 
selection medium was added, and protein expression was controlled by western blot or 
Luciferase assay. 
2.2.3 Cell cultures 
FTC133 is a FLCN-deficient human follicular thyroid carcinoma and was originally obtained 
from the American type culture collection (ATCC) (Laviolette 2017). HEK293T cells were 
also purchased from ATCC. 
786-0 cells are derived from a clear cell renal adenocarcinoma were originally obtained from 
ATCC. 
Cells were incubated at 37°C with 5% CO2 and grown in Dulbecco’s modified eagle medium 
(DMEM) with 10% fetal bovine serum (FBS) and 1% of Dulbecco’s antibiotic mix of 
penicillin, streptomycin and glutamine if not stated otherwise. This mix is later referred to as 
regular DMEM. 
2.2.4 Incubation of cell cultures with HIF inhibitors 
All investigated compounds were synthesized by the laboratory of drug discovery in 
neurodegeneration. Upon arrival at the lab, compounds were dissolved in dimethyl sulfoxide 
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(DMSO) to a concentration of 25mM in a clean tissue culture hood. Dissolved compounds 
were aliquoted and stored at -80°C. 
For treatment of cells, compounds were added to the usual cell medium (regular DMEM or 
selection medium supplemented with 2µg/ml puromycin for Luciferase assay) in 25 or 50mL 
falcon tubes. For example, to treat 786-O cells with a 10µM concentration of compound 83, 
4µL of the 25mM 83 stock solution was added to 10mL of regular DMEM at 37°C. As 
control, 4µL of DMSO, also aliquoted and stored at -80°C, was added to another 10mL of 
regular DMEM. Old medium of cell plates was aspirated, and the treatment medium was 
added carefully to the plates. 
2.2.5 Xenograft injections 
Animal experiments were carried out following the guidelines of the MGH institutional 
animal care and use committee according to an approved protocol. Cell lines were detached 
from cell plates using trypsin, washed and resuspended in phosphate buffered saline (PBS) 
and counted using a hemocytometer. Approximately 10 million cells resuspended in PBS 
with a total volume of around 300µL were injected subcutaneously into the right flanks of 
nude mice. 
Four mice were injected for each cell line to be tested and tumor volume was regularly 
measured by a caliper and calculated using the equation length(mm) x width2(mm2)/2. 
Tumors were harvested 47 days post injection. 
2.2.6 Luciferase assay 
This assay was conducted as described before (Zimmer et al. 2008). The 786-O cell line was 
used for this assay. To test the reduction of HIF2a translation through the compounds, 786-
O cells were stably transduced with a plasmid coding for firefly luciferase under the control 
of 4 sequences of hypoxia responsive elements (later referred to as 7H4 cells). HIF2a binds 
to specific DNA sequences termed hypoxia responsive elements (HRE) transactivating their 
target genes. Control cells were stably transduced with a Luciferase reporter constitutively 
active through the SV40 promoter, in a HIF-independent way (Later referred to as 7SV40 
cells). Transduced cells were selected using regular DMEM supplemented with 2µg/ml 
puromycin. The luciferase activity of 7H4 cells represents overall HIF2a activity in the cells. 
Here, the luciferase reporter is only transactivated by HIF2a. If the cells are treated with 
compounds inhibiting HIF2a translation, the overall HIF2a protein levels are reduced and 
therefore the overall HIF2a activity is suppressed; as a result, HIF2a inhibitors specifically 
reduce Luciferase activity in 7H4 cells but not in the control 7SV40 cells. 
Cells were counted and plated on 24-well plates to a confluence of 50% and incubated with 
the regular selection medium overnight. Cells were then treated with the compound to be 
tested, at various concentrations (usually 5 and 10µM) for 6-8 hours and harvested with 90-
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100% confluence. To detect the firefly luciferase activity, the Promega luciferase assay 
System (E1910) was used as described in the manual. Cells were grown on 24-well plates and 
three wells were treated with the same compounds each. Cells were washed on ice with cold 
PBS twice before 100µL of 1x passive lysis buffer was added. Plates were incubated on a 
rocker at 4°C for 30minutes. 70µL of each sample were then transferred onto a 96-well plate 
to allow faster pipetting with multi-channel pipets. To normalize the Luciferase signal to the 
total protein concentration of each lysate, protein concentration was measured by Bradford 
assay system (Bio-Rad #5000006). 
To measure the luciferase signal, 10µL of each sample was transferred onto a white 96-well 
plate and 10µL of luciferase assay reagent was added. The signal was then measured in a 
luminometer using the Softmax Pro software. 
2.2.7 Cell lysis 
Prior to cell lysis, plates were washed on ice with cold PBS five times. Cells were then scraped 
in 1mL PBS into eppendorf tubes and spun down at around 2g for 10minutes at 4°C. PBS 
was removed completely and the cell pellet was resuspended in 50µL of EBC lysis buffer 
(containing 50mM Tris(hydroxymethyl) aminomethane (Tris), 120mM sodium chloride 
(NaCl) and 1% Nonidet P-40 (NP-40)), supplemented with proteinase and phosphatase 
inhibitors. Cells were incubated on ice for 30 minutes. Samples were then centrifuged again 
at 4°C and 13,200 rpm for 15 minutes to clear them of cellular debris and supernatant was 
transferred into a clean tube. 
2.2.8 Click chemistry 
The term click chemistry is used to describe chemical reactions that are biocompatible and 
join substrates with specific biomolecules (bioconjugation). This term evolved first in the 
process of synthesizing complex molecular structures by joining small units together (Kolb 
et al. 2001). Today click chemistry has many applications among them molecular synthesis, 
labeling or isolation of compounds. The most common type of click reaction is a Huisgen 
azide-alkyne cycloaddition between an azide and an alkyne group, forming a strong covalent 
bond (Figure 6). This method was used here to biotinylate compound 83, which includes an 
alkyne group in its structure, with biotin-azide. To perform the reaction the Click-It protein 
reaction buffer kit by Invitrogen was used according to the manufacturer’s instructions 
(#C10276). 
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Figure 6: Copper-catalyzed azide-alkyne cycloaddition (Georgia Tech 2015) 
Briefly, after cell lysis with EBC lysis buffer, 55µL of the cell lysates were mixed with all 
reaction reagents as indicated by the kit’s instruction, including 100µL of reagent A 
supplemented with 40µM biotin-azide and incubated at room temperature for 20 minutes on 
a rotator. Afterwards proteins were precipitated using methanol and chloroform to wash off 
all reaction reagents. 600µL of methanol was added to each sample following 150µL of 
chloroform. After vortexing the samples shortly, 400µL of ddH2O was added and samples 
were centrifuged at 18,000g for 5 minutes. The precipitated proteins then form a pellet 
between the lower hydrophobic phase and the upper aqueous phase. The upper phase is then 
carefully removed without disturbing the pellet which is then washed in 450µL of methanol 
twice. In between the washing steps the pellet is spun down again as stated before. After air 
drying the pellet with open lids for about 4 minutes it can be resuspended in 60µL of EBC 
lysis buffer, although concentrations of this buffer were optimized later (see results). 
2.2.9 Isolation via click reaction to azide coated beads 
For this procedure I used the Click-It protein enrichment kit form Invitrogen. 786-0 cells 
were treated with 10µM of each compound 83 or 76 for 16 hours. Cells were washed three 
times with PBS and lysed in EBC lysis buffer including protease and phosphatase inhibitors 
as stated above. For each sample, 30µL of azide magnetic beads were washed twice with 
PBS-T (0.02% tween 20 in PBS), before 500µL of the lysates were added. To start the 
reaction, 500µL of 2x copper catalyst solution was added to each sample. The copper catalyst 
solution was prepared as stated by the kit’s instructions. 1mL of the 2x solution contains 
835mL of ddH2O, 125µL additive 1, 20µL of 100mM copper(II)sulfate solution and 20µL 
of additive 2. Samples were rotated end-over-end for 16-20 hours at 4°C. 
Following the click reaction each sample was washed 5 times with NT-N buffer containing 
100mM NaCl, 20mM tris and 0.5% NP-40. The beads were then resuspended in 500µL of 
this buffer and submitted for mass spectrometry analysis which was performed by a partner 
lab. 
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2.2.10 Immunoprecipitation and protein isolation via streptavidin 
For immunoprecipitation, cells were lysed with EBC lysis buffer as described above. 30µL 
per sample of magnetic protein A dynabeads were washed twice with PBS supplemented 
with 0.02% Tween 20 (PBS-T) and resuspended in 600µL of the washing solution. Anti 
FLCN antibody was added and tubes were rotated for two hours at 4°C. 
Coupled beads were again washed twice with PBS-T before the cell lysates were added and 
samples were again rotated at 4°C for 2.5 hours. Afterwards beads were washed 5 times with 
NET-N buffer (containing 100mM NaCl, 20mM Tris, 1mM EDTA and 0.5% NP-40). To 
separate the proteins from the beads, they were boiled for 5 minutes at 95°C in SDS-PAGE 
sample buffer (containing 60mM tris, 2% SDS, 10% glycerol and 0.003% bromophenol 
blue). 
To isolate biotinylated compound 83 and bound proteins, samples were incubated with 50µL 
of magnetic streptavidin dynabeads for 30 minutes at room temperature. Beads were then 
washed five times with NT-NS buffer containing 500mM NaCl and 1% SDS. Proteins were 
released from beads through boiling in 20µL of 1.5x sample buffer (92.85mM tris, 3% SDS, 
17.5% glycerol and 0.005% bromophenol blue) at 95°C for five minutes. 
2.2.11 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE allows the separation of proteins by their molecular mass in a polyacrylamide 
gel using an electric field. The method was first described by Laemmli (1970). The first step 
is the production of a polyacrylamide gel. This was poured in between two glass plates that 
were wiped clean with 70% ethanol and separated by three plastic spacers, held together with 
paper clips. This gel cast was sealed using a 1% agarose (Sigma Aldrich #A2576) solution. 
The higher the polyacrylamide concentration in the gel, the smaller are the pores of the gel, 
through which the proteins wander. The polyacrylamide gel concentration should be 
adjusted to the molecular mass of the proteins to be separated. Here, I only used 8.75% 
polyacrylamide gels. 
Table 5: Polyacrylamide gels 
polyacrylamide gels 
Ingredients Separating gel (8.75%) Stacking gel 
ddH2O 8.84mL 6.34mL 
0.5M Tris, 0.4% SDS - 2.5mL 
1.5M Tris, 0.4% SDS 5mL - 
30% Acrylamide 5.85mL 1.34mL 
10% Ammonium persulfate 200µL 150µL 
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Ingredients Separating gel (8.75%) Stacking gel 
N, N, N’, N’-tetramethyl-
ethylenediamine (TEMED) 
5µL 20µL 
The lower, separating gel is poured into the glass cast first. 1mL of pure butanol was poured 
on top of the gel carefully to get rid of any air bubbles and ensure a smooth interface. After 
polymerization (about 1 hour) the butanol was rinsed off with water and the stacking gel was 
poured on top before inserting a plastic comb, forming pockets for the samples inside the 
stacking gel. The stacking gel measured at least 2cm from the bottom of the pockets. Once 
both gels are polymerized and proved for at least 1 hour, the plastic comb and the bottom 
spacer can be carefully removed, and the gel can be placed in an electrophoresis apparatus. 
The apparatus is then flooded with SDS running buffer (25mM Tris, 192mM Glycine and 
0.1% SDS). 
Prior to loading the gel, cell lysates were boiled for 5 minutes at 95°C in a 3x SDS loading 
buffer containing 185.7mM tris, 6% SDS, 35% glycerol and 0.01% bromophenol blue. SDS 
is a negatively loaded detergent that binds to proteins covering their own charges. To make 
sure that all samples run through the gel at the same speed the same volume of sample buffer 
and therefore the same amount of SDS has to be loaded into each well of the gel. By boiling 
the samples in this buffer, proteins are precipitated, and the rejection of their negative 
charges unfolds the proteins, allowing their separation in the gel by molecular mass. Longer 
proteins with a higher molecular mass run through the gel slower than shorter proteins. On 
both sides of the samples, a protein ladder (Precision Plus Protein Kaleidoscope) was loaded 
into the gel. 
To separate the proteins, an electric field is generated in the gel (60 mA while in stacking gel, 
40mA in separating gel, constant 250mV). When in solution, particles in an electric field are 
drawn to the pole with the opposite charge. Through SDS, all proteins are negatively charged 
and therefore drawn to the positively charged pole of the electric field, the anode, that is 
generated in the lower part of the gel. 
2.2.12 Western blot 
Proteins separated in size through SDS-PAGE were then transferred again using an electric 
field onto a polyvinylidene fluoride (PVDF) membrane in a semi-dry transfer system. In this 
procedure, gel and membrane are put on top of each other between an electric field. Because 
of their negative charge, proteins again are drawn to the anode of the electric field and stick 
to the PVDF membrane, building hydrophobic and polar interactions. 
The gel was carefully removed from the gel cast and the upper stacking gel and agarose 
sealing layer were removed. The gel was then transferred into the cathode buffer, containing 
25mM tris, 142mM glycine and 10% methanol. Inside the transfer machine, 3 layers of filter 
paper (Whatman) soaked in anode buffer I, containing 0.3M tris and 10% methanol were 
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placed. It is important to make sure that no air bubbles are trapped in between layers of filter 
paper since they interrupt the electric field. Meanwhile the membrane is “activated” in 100% 
methanol for 1 minute. This process helps to remove the hydrophobic characteristics of the 
membrane and increases its interaction in the anode buffer II, containing 25mM tris and 
10% methanol in which it is soaked before placing it on the filter paper stack. The gel is then 
placed directly on the membrane carefully, avoiding air bubbles again. On the gel, another 
three filter papers soaked in cathode buffer are placed and the “sandwich” is closed. Then 
an electric current is applied to the system using 15V and 500mA for 60 minutes. This forces 
proteins out of the gel that is on the cathode side of the field and onto the membrane towards 
the anode. Proteins stick to the membrane via hydrophobic and polar interactions. 
After the transfer the membrane was incubated in blocking buffer containing 4% bovine 
serum albumin, 10mM tris, 150mM NaCl and 0.5% Tween 20, for 60minutes. This process 
blocks all the open spots of the membrane, avoiding unspecific protein binding. 
In order to detect one specific protein on the membrane, it is incubated with blocking buffer 
supplemented with an antibody targeting the protein of interest overnight at 4°C. The 
membrane was cut with a razor blade to incubate different parts of the membrane with 
different antibodies. The standard protein ladder visible from SDS-PAGE was used for 
orientation to cut the membrane. 
To visualize the primary antibody, it is stained with a secondary antibody (anti-rabbit or anti-
mouse) bound to horseradish peroxide (HRP). Before incubation with the secondary 
antibody, the membrane is washed three times for 15 minutes with TBS-T (10mM tris, 
150mM NaCl and 0.5% Tween 20) at room temperature. Secondary antibody was then 
applied in TBS-T as well for 60 minutes in a dilution of 1:10,000. The membrane is then 
washed again three times as described before. The targets are visualized through short 
incubation with a developing solution (Western Lightning Plus-ECL, Perkin Elmer) and 
detected with a Bio-Rad ChemiDoc system. 
To stain the PVDF membrane for biotinylated compound 83, it was incubated with 
streptavidin-HRP right after the transfer for 1hour at room temperature with light agitation. 
Instead of using blocking buffer, TBS-T was supplemented with 5% milk powder and 
streptavidin-HRP was added in a dilution of 1:2,000. The membrane was then washed three 
times in TBS-T and developed as described above. 
To detect proteins by ponceau S the membrane was incubated with ponceau S solution 
containing 0.1% ponceau S and 5% acetic acid in ddH2O for 1 hour at 4°C with light 
agitation. It was then washed in ddH2O until clear bands were visible. 
2.2.13 Silver nitrate staining of polyacrylamide gels 
Proteins in the polyacrylamide gel after electrophoresis were fixed overnight in a ddH2O 
based solution containing 20% methanol and 10% acetic acid. Gels were then washed for 
2 Materials and methods 22 
30minutes in a 50% ethanol solution followed by a second wash with only ddH2O for 15 
minutes. They were then incubated for 15minutes in 300mL ddH2O containing 25µL of a 
1M dithiothreitol (DTT) stock solution followed by one hour of incubation in a 0.2% silver 
nitrate solution. Gels were developed in a 3% sodium carbonate and 0.02% formaldehyde 
solution up to the desired contrast for about 10-15 minutes. The reaction was stopped by 
washing the gel in 1% acetic acid solution. 
Desired gel sections were cut out using a clean razor blade and stored in Eppendorf tubes. 
To destain gel sections two destaining solutions were prepared. Solution 1 was 60mM 
potassium ferricyanide (Sigma Aldrich #244023) and solution 2 200mM of sodium 
thiosulfate (Sigma Aldrich #72049) in ddH2O. These solutions were mixed 1:1 and 400µL 
of the mixture was added to each gel section and incubated for 5 minutes at room 
temperature. Gel sections were then washed with ddH2O until they were clear about 5 times 
for 5 minutes and submitted to the Taplin mass spectrometry facility of Harvard Medical 
School for mass spectrometry analysis. 
2.2.14 Mass spectrometry analysis 
Mass spectrometry analysis was performed by members of the Haas laboratory of the 
Massachusetts General Hospital Center for Cancer Research. The procedure was described 
previously by Lyons et al. in 2018. Disulfide bonds were reduced using DTT and cysteine 
residues alkylated with iodoacetamide. A two-step process was then used to digest proteins. 
The first step was digestion with 3µg of endoproteinase LysC at room temperature overnight 
following 6 hours of 3µg of sequencing-grade trypsin at 37°C. The reaction was stopped with 
trifluoroacetic acid. The digest was then separated from the azide magnetic beads. To desalt 
the samples, they were run through solid-phase extraction cartridges (Sep-Pak C18). Peptides 
were then vacuum dried and stored at -80°C. 
Mass spectrometry analysis of silver stained SDS-PAGE gel was performed by the Taplin 
Mass Spectrometry Facility of Harvard Medical School. Reduction, alkylation and digestion 
of the proteins were performed before extracting the peptides from the gel. 
For labeling with tandem mass tag reagents, peptides were resuspended in 200mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 8.5), 30% acetonitrile, and 5 
µL of tandem mass tag reagent, suspended in 30% dry acetonitrile as well. Samples were 
incubated for 1 hour at room temperature and the reaction was stopped by adding 6µL of 
5% hydrolxylamine in 200mM HEPES solution. Solutions were again acidified with 50µL of 
1% trifluoroacetic acid and desalted as described earlier. 
Samples were then fractionated by basic pH reversed-phase liquid chromatography sample 
fractionation. Resuspended samples were separated using a 4.6mmx250mm Zorbax Extend-
C18 column on an Agilent 1260 high-performance liquid chromatography system. 
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For mass spectrometry data acquisition, tandem mass tagged peptides were subjected to 
multiplexed quantitative proteomics analysis on an Orbitrap Fusion mass spectrometer. 
After separation over different micropapillary columns, samples were eluted, and peptides 
were identified using MS2 spectra and quantified with MultiNotch MS3 method in a data-
dependent mode (McAlistor et al. 2014). The acquired data was analyzed through an in-house 
SEQUEST-based software platform (Eng et al. 1994). 
3 Results 24 
3 Results 
3.1 A novel FLCN mutation promoting tumor growth in vivo 
3.1.1 “Early onset renal cell carcinoma in an adolescent girl with germline FLCN 
exon 5 deletion” (Schneider et al. 2018) 
The results presented here have been published as a case report titled “Early onset renal cell 
carcinoma in an adolescent girl with germline FLCN exon 5 deletion” by Meike Schneider, 
Katja Dinkelborg et al. in the Familial Cancer journal (Schneider et al. 2018). We report on 
a 14-year-old girl with RCC of the left kidney who was referred to the Massachusetts General 
Hospital genitourinary cancer genetics clinic. Except for a palpable abdominal mass, physical 
examination of the patient and the medical history were unremarkable. 
The patient underwent nephrectomy of the left kidney. Histological as well as 
immunohistochemical examination of the tumor failed to classify the tumor as one of the 
known histologic entities. Genetic testing however revealed an in-frame deletion of exon 5 
in the FLCN gene (p.Gly84_Glu-132del in exon 5) (Figure 7a). The patient’s father carries 
the same FLCN mutation, but he has no renal cysts or masses by abdominal magnetic 
resonance imaging (MRI). Neither the index patient nor her father or any of the father’s 
relatives had a history of RCC. Furthermore, there was no history of any skin 
fibrofolliculomas or spontaneous pneumothorax. 
3.1.2 FLCN germline intragenic deletion encodes a stable protein when 
reintroduced in FLCN-null cells 
Given the lack of family history or other phenotypical BHD characteristics, as well as the 
early onset of RCC in this patient, it was important to show that the genetic mutation leading 
to the altered FLCN protein was responsible for the proband’s tumor. To test this, we cloned 
the mutant FLCN into a tumor cell line, proved expression of stable protein and tested 
whether the insertion lead to a tumorigenic phenotype. To this end a new plasmid encoding 
a FLAG-tagged FLCN protein harboring the patient’s FLCN mutation was designed (see 
2.2.1 for detailed information). A pBabe-puromycin plasmid expressing WT FLCN protein 
was used as template (already present in the lab, Laviolette et al. 2017). 
FLCN-null FTC133 cells were stably transcribed with WT FLCN, FLCN harboring the 
patient’s deletion (FLCNdel5) or empty vector as control. Western blot of stably infected 
cell lines showed a stable protein encoded by the FLCNdel5 mutant (Figure 7b). The lower 
molecular weight is consistent with the 48 amino acid deletion and the finding that the band 
on the gel has the same intensity as the wildtype FLCN transfected protein indicates that the 
mutant protein is transcribed at an equivalent level and stable. 
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3.1.3 In vivo assay shows loss of tumor growth suppression by FLCN mutant 
To assay for the effect of this mutant on the function of FLCN, FLCN-null FTC133 cells 
infected with WT FLCN, the patient’s FLCN mutant or empty vector as control were 
injected in the flank of nude mice. Cells expressing FLCN WT did not form a tumor (Figure 
7c, d). In contrast to WT expressing cells, cells that expressed the FLCNdel5 or infected with 
empty vector generated tumors in mice. Taken together these results show that the in-frame 
mutation is encoding a stable protein that has lost its ability to suppress tumor growth. The 
in vivo tumor suppression assay was used, in our case, to evaluate the functional outcome of 
a clinically identified mutation, the nature of which could not be a priori predicted by its 
molecular changes. Thus, the tumor xenograft assay is a validated approach to test the 
functional effect of novel FLCN mutations. 
 
 
Figure 7: “Patient’s germline in-frame mutation inactivates FLCN tumor suppressor gene.” 
(Schneider et al. 2018) 
A “Exon level CGH microarray reveals deletion in FLCN gene. B FLCN p.Gly84_Glu132del 
encodes a stable protein when reintroduced in FLCN-null cells. FLCN protein was 
immunoprecipitated by anti-FLCN antibody from cells stably infected with vector only, wild type 
FLCN gene or the FCLN p.Gly84_Glu132del mutant, as indicated. Immunoprecipitated proteins 
were detected by immunoblot with the same anti-FLCN antibody. C-D Reintroduction of FLCN 
wild type but not the FLCN p.Gly84_Glu132del mutant in FTC133 FLCN-null cells suppresses their 
growth as tumor xenografts in immunocompromised mice. Asterisk indicates comparison to FLN 
WT corresponding value, p<0.02, Student’s t test.” (Schneider et al. 2018, with kind permission of 
Familial Cancer) 
Unpublished data from the Iliopoulos laboratory, currently under review, showed the 
interaction of FLCN with two translation initiation factors. FLCN downregulated protein 
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translation in an mTOR independent manner. The c-terminal region of FLCN is crucial for 
this interaction. Interestingly, in this patients’ mutation the c-terminal region remains intact. 
Nonetheless the mutant is tumorigenic implicating an important function of region Gly184-
Glu132. This suggests that the region of FLCN encoded by exon five is crucial for its 
function. 
3.2 Identification of  proteins involved in HIF regulation 
3.2.1 Compound 83 can be modified by click-chemistry and is active 
The goal of this effort is to identify cellular proteins interacting directly with the HIF2a small 
molecule inhibitors. As compound 76 was used in different studies in the lab confirming its 
function, its structure was used as orientation for further experiments to identify target 
proteins. Compound 76 consists of a thiophene core with two different functional arms 
bound to it. One arm consists of a ester group and the other is bound via hydrazine group 
and has a sulfur dioxide group at the end (Figure 8a). Compound 76 has a molecular mass 
of 287g/mol. 
To be able to isolate the compound from a cell lysate we substituted the methyl group of the 
ester arm with an azide group and called this compound 83 (Figure 8a). The method that 
was used to synthesize this compound was published by Wang et al. (2019). Compound 83 
has a slightly higher molecular weight of 311g/mol. Luciferase assays confirmed its unaltered 
activity compared to 76 (Figure 8a). 
3.2.2 Visualization of protein bands bound by compound 83 
Lysates of cells treated with compound 83 or DMSO control were processed in a click 
reaction to link biotin to the small molecule inhibitor. Biotin was covalently bound via an 
alkyne group to the azide group of compound 83 but not to compound 76 which does not 
contain the azide group. Following the click reaction, cellular proteins were precipitated (as 
described in the methods), resuspended and separated by SDS-PAGE. Electrophoresed 
proteins were transferred to a PVDF membrane and western blotted with streptavidin HRP. 
Results showed a specific reproducible pattern of protein bands, detected by streptavidin 
(Figure 8b). 
To separate the proteins by size in an SDS-PAGE, the procedure includes boiling the 
samples in 3% SDS buffer. This step of the procedure precipitates the proteins and usually 
breaks down non-covalent interactions within their molecular structure or between different 
proteins. If compound 83 binds its target proteins in a non-covalent way, this interaction 
would be broken as well. In this case, the compound alone would run through the SDS-
PAGE and the streptavidin staining would not identify protein bands. These data therefore 
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strongly suggest that compound 83 binds covalently to a specific set of target proteins. 
However, it is not clear how compound 83 and its analogs bind the proteins. 
To control for non-specific binding of compound 83 to cellular proteins, cells were treated 
with compound 671. This latter compound is similar to 83 and bears an azide group that can 
“click” with the alkyne group of biotin. In contrast to compound 83, compound 761 was 
modified so that it does not inhibit HIF2a activity in a luciferase assay. It is including the 
azide group, but without showing any activity in the luciferase assay (Compound 671). The 
hypothesis is that since compound 761 does not inhibit HIF2a function it does not form 
covalent bonds with the protein targets critical for suppression of HIF2a translation. Indeed 
compound 671 appeared not to interact covalently with endogenous proteins (Figure 8b). 
In addition, to control for non-specific binding of biotin to cellular proteins, we used 
compound 76 treated cells for a click reaction. Compound 76 does not display an azide group 
and therefore any protein detected by biotin streptavidin interaction can be attributed to 
non-specific binding of biotin directly to the protein but not to the interaction of the 
chemical inhibitor to the target protein. Similarly, to compound 761, treatment with 
compound 76 did not lead to the detection of target proteins (Figure 8b). The experiments 
using compound 76 and 761 confirmed the specificity of the procedure. They indicate that 
compound 83 interacts specifically with a set of proteins likely involved in suppression of 
HIF2a translation and that the assay we used to identify proteins is specific to the interaction 
of compound 83 to its target. 
To further validate the specificity of this assay, we tested the hypothesis that if compound 
76 and 83 bind to the same proteins they may “compete” with each other for binding. We 
treated cells with a combination of compound 76 (active but not clickable) and compound 
83 (active and clickable). Both, compounds 76 and 83, should bind the same proteins but 
only those bound to 83 are biotinylated via click reaction and stained with streptavidin on 
the membrane. Indeed, we showed that “cold” compound 76 competes with compound 83 
for protein binding. The biotinylation of protein targets through binding of compound 83 
for was reduced by treatment with compound 76 (Figure 8c). 
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Figure 8: Compounds' structure, activity, and bound proteins. 
A Activity of the compounds is shown through luciferase assay. The graphs in grey represent the 
relative luciferase signal from control cells, stably infected with a constitutively expressed firefly 
luciferase reporter. Red graphs represent the luciferase expression regulated through hypoxia 
responsive elements (HRE), only active when bound by HIF. A reduced luciferase signal represents 
a lower concentration of HIF in the cells. Compound 83 is as active as lead compound 76 whereas 
compound 671 does not show activity in downregulating HIF translation. B Western Blot of lysates 
of cells treated with different compounds (5µM) each for 8-10 hours. A click reaction with biotin-
azide was performed and through the biotinylation of compound 83 protein bands of its covalently 
bound proteins are stained with streptavidin HRP. C Same protocol as described in b with the 
difference of simultaneous treatment to see if other active compounds compete with compound 83 
in binding the target proteins, therefore reducing signal in simultaneously treated cells compared to 
cells only treated with compound 83. 
3.2.3 Isolation of cellular proteins interacting with HIF2a inhibitors 
Identification of the proteins bound to the lead compounds, requires their isolation from all 
other proteins in the cell lysates. For this isolation we used streptavidin coated beads. Cells 
were incubated with compound 83 overnight. After cell lysis and performing the click 
reaction that biotinylates compound 83, samples were incubated with streptavidin beads. The 
beads were then washed, and the biotin-streptavidin interaction was broken by boiling the 
samples. Eluted proteins were resolved in SDS-PAGE, transferred to a PVDF membrane 
and detected by streptavidin HRP. 
This experiment showed the pattern of eluted proteins of the whole lysate as described 
previously in paragraph 3.2.2 (Figure 9a). The isolation procedure did not alter appreciably 
the composition of the biotinylated proteins. 
The streptavidin HRP staining can only detect proteins covalently interacting with 
biotinylated compounds. To check for unspecific binding to beads (background), the same 
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membrane was stained with a Ponceau S solution. In contrast to staining with streptavidin, 
Ponceau S stains all proteins, independently of their interaction with HIF2a inhibitors. 
Ponceau S staining revealed that there is a significant degree of non-specific binding of 
proteins to the beads (Figure 9b). However, this again confirmed the specificity of detecting 
proteins that interact with HIF2a inhibitors by streptavidin staining after treating cells with 
the biotin loaded compounds. 
 
Figure 9: Isolation of the compounds and bound proteins by a streptavidin pull-down assay. 
A 786-0 cells were treated with compound 76, 83 or vector only control (DMSO). After 12h of 
treatment, cells were lysed and compound 83 was biotinylated via click reaction. streptavidin coated 
beads were added to samples and rotated for 30min. Beads were washed, and proteins boiled of in 
SDS buffer for SDS-PAGE. Western blot was stained with streptavidin-HRP. streptavidin pull-down 
shows a similar protein band pattern as only biotinylation (Figure 8b). B Ponceau S staining of the 
same membrane shows high background in control cells treated with compound 76. 
3.2.4 Resolving of a high protein background 
In an effort to reduce the non-specific protein background, we tried optimization of different 
steps of the protocol. The first problematic step seemed to be the complete suspension of 
the protein pellet after the click reaction. To separate the product of the click reaction from 
the reagents, proteins are precipitated with methanol and chloroform. For the isolation, it is 
crucial that the pellets are suspended completely in a sodium dodecyl sulfate (SDS) 
containing buffer. 
At first, we used EBC lysis buffer for suspension of the pellet. This buffer contains 1% SDS. 
The samples were heated to 70°C for 10 minutes. To get rid of flakes remaining from the 
protein pellet, we increased both the SDS concentration of the buffer and the heating 
3 Results 30 
temperature. In addition, samples were centrifuged though glass wool at 18,000g for 5 
minutes. The best results were gained with SDS concentration of 2% and boiling at 95°C for 
5 minutes (Figure 10a). 
In another approach to resolve unspecific protein background, different wash buffers were 
tested. Here we varied both the NaCl and SDS concentrations in a NT-N buffer containing 
NaCl, 20mM Tris and NP-40. When we washed the beads that “pulled down” the proteins 
with buffer containing 500mM NaCl and 1% SDS we were able to significantly reduce the 
non-specific binding of proteins to beads (Figure 10b). 
 
Figure 10: Optimization of streptavidin pull-down. 
A Streptavidin pull-down of 786-0 cells treated with compound 83 or DMSO (vec) overnight. 
Different conditions were used for the resuspension of the precipitated protein pellet after click 
reaction. After washing with methanol, pellets were suspended in 50mM Tris buffer with different 
SDS concentrations as stated in the table. Samples were then heated for 5min to different 
temperatures to facilitate suspension. B After isolation of biotinylated compound 83 and bound 
proteins with streptavidin coated beads, different wash buffers were used to clean beads of unspecific 
bound proteins. All wash buffers contained 20mM Tris-HCl, 0.5% Nonidet P-40. NaCl 
concentrations were increased in buffers with or without adding SDS. Even with 500mM NaCl and 
1% SDS clear results can be obtained. 
3.2.5 Identification of candidate target proteins 
Different approaches were taken to identify the proteins in the bands visible when detected 
by streptavidin-HRP: Multidimensional protein identification technology (MudPIT) and 
SDS-PAGE protein separation followed by selected protein elution and spectrometry. 
As a first approach the candidate target proteins were pulled-down via a direct click reaction 
to azide magnetic beads (Click Chemistry Tools #1036-1). Lysates of cells treated with 
compound 83 or compound 76 were used. After the click reaction the beads were washed in 
a wash buffer containing 100mM NaCl, 20mM Tris and 0.5% NP-40. The beads were 
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submitted to a partner lab for on resin digestion followed by mass spectrometry analysis. To 
ensure reproducibility, four “positive” samples of cells treated with compound 83 and four 
“negative” samples of cells treated with compound 76 were analyzed. Spectrometry analysis 
produced a list of proteins isolated from cells treated with compound 83 or 76. 
From this analysis we compared the averages of the number of peptides identified from all 
samples treated with 76 with the averages of the four samples treated with compound 83. 
We then considered only the proteins identified at least twice as often as in the samples 
treated with 83. This gave us a list of 58 proteins. 
Specific criteria were applied to narrow down the list of proteins that are candidate targets 
of the compound: 1) Only the proteins identified by at least two different peptides were 
considered, 2) The proteins that were abundant so that they produce at least a total of 10 
peptideswere considered, 3) From the subset that conformed to all the criteria listed in 1 and 
2, the proteins with the predicted molecular weights corresponding to pull-down bands 
resolved by SDS-PAGE and detected by streptavidin HRP staining were considered (Figure 
11a). Based on criteria 1-3, the following proteins constitute a “short list” of direct targets of 
HIF2a inhibitors: a) peflin 1, a 30kDa calcium binding protein, b) YRDC, a mitochondrial 
protein (29 kDa), and c) FAM133B (28kDa), which may be involved in RNA binding. 
Unfortunately, using this approach, we could not identify any proteins that could represent 
the strong band visible in the pull-downs at around 100kDa. Because this experiment was 
done with azide coated beads, we could not optimize the purification of these samples to the 
same extend as described earlier with streptavidin coated beads. In this experiment the beads 
were washed less stringent than the streptavidin coated beads. 
As a second approach, proteins isolated by pull-down of lysates treated with 83 or DMSO 
with streptavidin coated beads were resolved by SDS-PAGE. Proteins in the gel were then 
stained with silver nitrate (Figure 11a). Protein bands detected by silver nitrate in the lysates 
of cells treated with 83 but absent in the lysates of cells treated with DMSO were considered 
specific. We cut these bands out of the gel and submitted the gel content to in gel digest and 
mass spectrometry to the Taplin mass spectrometry facility of Harvard Medical School in 
order to identify the protein(s) represented by the band. As controls we used the 
corresponding gel area in the lane resolving the proteins pulled down from cells treated with 
DMSO. In total, we submitted 5 samples from each lane. The samples were cut out from 
around 170kDa, 100-150kDa, 100kDa, 45kDa, and 30kDa (Figure 11b). In this approach 
fewer proteins were identified in each sample since only a part of the whole lysate was 
analyzed. To again narrow down the list of proteins similar criteria as mentioned above were 
applied. 1) Only the proteins with the molecular weight corresponding to the gel area that 
the sample had been cut out from were considered specific. 2) Only the proteins that were 
identified in the 83 lane but not in the corresponding section of the DMSO lane were 
considered. The following proteins were identified through this approach: a) iron regulatory 
protein 1 (IRP1, 98kDa), b) tumor susceptibility gene 101 (TSG101, 44kDa), and c) 
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phosphoglycerate kinase 1 (PGK1, 45kDa). When secreted by tumor cells, PGK1 acts as a 
disulphide reductase, enabling tumor angiogenesis (Lay et al. 2000). Interestingly, peflin was 
also identified by mass spectrometry analysis of section 5 (Figure 11b). 
Taken together, the second isolation procedure was much more optimized prior to mass 
spectrometry analysis and might be a cleaner approach. Interestingly, it confirmed interaction 
of the compounds to IRP1, which was also suggested as a possible target protein in earlier 
studies (Zimmer et al. 2008), following a completely different approach, thus validating the 
pull-down. Also, peflin was identified as a candidate target by both procedures. However, 
apart from peflin, the analysis led to different results and should be validated by repetition 
or further investigation in the identified proteins. 
 
Figure 11: Identification of candidate target proteins. 
A Protein lane taken from figure 10b with bands and their approximate molecular weight indicating 
identified proteins by mass spectrometry analysis. B Silver-nitrate stained polyacrylamide gel after 
electrophoresis showing lysates of cells treated with DMSO or compound 83. After a click reaction 
with biotin-azide proteins where isolated using streptavidin coated beads. C Western blot of 
corresponding lysates from A. Western blot incubated with either anti-peflin or anti-IRP1 antibodies 
show positive results for cells treated with compound 83 but not DMSO. 
To validate the proteins identified by mass spectrometry analysis we western blotted cell 
lysates as described above for the suggested target proteins. For this experiment the same 
pull-down protocol as described above (3.2.3) was used.  Cells were treated with compound 
83 or DMSO, after cell lysis a click reaction with biotin-azide was performed, compound 83 
and its bound proteins were isolated with streptavidin coated beads. After SDS-PAGE and 
transfer to a PVDF membrane, instead of staining the membrane with streptavidin HRP as 
before it was now incubated with antibodies against the identified candidate target proteins, 
YRDC, FAM133B, peflin and IRP1. Both peflin and IRP1 showed positive results suggesting 
the binding of the compounds to these proteins (Figure 11c). TSG101 and PGK1 have not 
been tested using this assay. 
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4 Discussion 
4.1 Can we predict whether a novel FLCN mutation leads to loss-of-
function and therefore to be tumorigenic in BHD syndrome? 
In hereditary diseases such as BHD syndrome it is not always given to predict how a specific 
mutation effects the proteins’ function. Here, we show through an in vivo assay, using mouse 
xenografts, that a novel FLCN mutation lead to a tumorigenic phenotype. In this case, it was 
specifically interesting because of the unusual family and patient history, but also because the 
mutation did not affect the c terminal region of the protein, as most mutations in BHD 
syndrome do (Lim et al. 2010). 
The availability of a functional assay may expedite the clinical diagnosis by helping to 
functionally classify the mutation. In the long term this assay could be used to further look 
into a genotype-phenotype correlation in patients with BHD syndrome. Comparison of 
growth rate and histopathological features of grown xenografts with different FLCN 
mutations might lead to new insights into FLCN function and pathway regulation. 
Recommendations for patient surveillance suggest abdominal imaging for kidney tumor 
detection starting at the age of 20 (Jensen et al. 2017). Jensen et al. also recommend that 
abdominal scans are repeated every two years if a tumor is detected. Close surveillance is 
especially important to detect the aggressive, fast growing RCC types among BHD patients. 
Patient surveillance and management could be more specific if the BHD phenotype could 
be predicted by the FLCN mutation detected in the patient. In addition, the publication of 
this case raises awareness of the possibility that the age of onset of RCC in a BHD patient 
may be as early as in adolescent years. This would strongly suggest that baseline screens for 
RCC in BHD patients is necessary as early as in adolescence. 
In addition, we report on a highly interesting case of BHD disease. We provide proof that a 
newly identified FLCN mutation, not affecting the c-terminal region of the protein, is a 
driving cause of RCC in a BHD patient. Since most of the detected FLCN interactions are 
linked to its c-terminal domain, this finding can provide new insight into FLCN structure or 
function. Especially since detection of the mutant protein by western blot analysis suggest a 
somewhat stable protein and the tumorigenic effect is not due to the loss of FLCN in total. 
These observations are especially interesting considering the recent structural identification 
of the FLCN/FNIP2 complex by Lawrence et al. and Shen et al. (2019). Both groups 
investigated the role this complex plays in serving as a GTPase activating domain to Rag C, 
leading to the activation of mTORC1 dependent on amino acid availability in the cell. Shen 
et al. found out that FLCN and FNIP2 heterodimerize via Longin domains that are localizing 
at the space between both nucleotide binding sites of RagA and RagC. The Longin domains 
are localized at the n-terminal regions of both proteins, placing the patients’ deletion from 
amino acid 84 to 132 within this region. 
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Even more we could identify the deleted region of the patients’ FLCN mutant to represent 
the αL1helix of FLCN, directly interacting with the nucleotide binding site of RagA (Figure 
12). This suggests that the patients’ FLCN mutant protein loses its function to activate GTP 
hydrolysis of Rag C enabling mTORC1 activation. In some way this hypothesis contradicts 
the assumption that FLCN, as a tumor suppressor protein, enables the activation of 
oncogenic pathways such as mTORC1. Upregulation of mTORC1 has been shown in BHD 
associated tumors (Hasumi et al. 2009). 
Although regulators of the nucleotide loading state of both RagA/B and C/D which control 
mTORC1 activation have been identified, the upstream regulation of these processes, that 
are linked to the amino acid availability in the cells remain to some extent unknown. This 
could suggest, that the FLCN mutation does not lead to the inability of mTORC1 activation 
Figure 12: Cryo-EM structure of FLCN-FNIP2-Rag-Ragulator complex from Protein Data Bank 
6ULG. 
Proteins are indicated by the following colors: FLCN in dark blue, FNIP2 in dark red, RagA in 
orange, Rag C in light red. Other colors represent the components of the Ragulator pentamer. The 
nucleotides bound by RagA and C are indicated by the globes. B shows part of the whole structure 
(a) enlarged. The red brackets indicate the amino acids deleted by the patients’ FLCN mutation 
delpG84-E132. The αL1 helix is deleted in the patients FLCN mutant protein. C shows Figure 3c 
from Shen et al. (2019) showing the interaction of the same αL1 helix with the nucleotide binding 
domain of RagA. Here FLCN is shown in purple, RagA in pink and FNIP2 in orange. With kind 
permission of Cell Press. 
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but rather enables its uncontrolled, constitutive activation, leading to oncogenic cell 
metabolism. Together with the structural findings of Shen et al. this shows a critical role, the 
n-terminal region of FLCN holds making these mutations crucial for BHD disease. 
So far, we cannot predict whether a specific FLCN mutation is tumorigenic. However, here 
we provide an in vivo assay that can be used to validate the tumorigenic effect a mutant 
protein withholds. Considering recent structural findings of the FLCN/FNIP2 complex the 
deleted protein section falls directly into a crucial αL1helix of the complex, regulating 
mTORC1 activation, again validating the driving force this mutation plays in tumorigenesis. 
In conclusion, these findings strongly suggest the investigation in how the loss of this 
function of FLCN might enable uncontrolled mTORC1 activity in tumor cells and could 
help in developing hypotheses as to how mTORC1 activation is linked to amino acid 
availability in the cell. A better understanding of what parts of the FLCN protein enable what 
function may lead to a prediction of the tumorigenic effect of FLCN mutations, improving 
therapy for BHD patients. 
4.2 Can specific target proteins be identified that bind to the small 
molecules generated by cell-based high throughput screen? 
4.2.1 Generation of specific small molecule analogs that are substrates for click 
chemistry that maintain activity 
The development of a facile synthetic route of compound 76 (Wang et al. 2019) allowed for 
the synthesis of compound 83 that can be used in click chemistry and is still active in 
inhibition of HIF2a translation. The ability to “click” compound 83 allows its isolation 
alongside interacting proteins from the cell lysate. Because the chemical reaction of the click 
chemistry produces a covalent bond between the substrates, we used the well-studied and 
easy to work with biotin-streptavidin interaction to try isolation of the compounds. This way, 
they can not only be stained as western blot using streptavidin HRP but also isolated using 
streptavidin coated beads. 
Using this approach, we could identify a specific and reproducible pattern of protein bands 
binding to compound 83. Purification of the compound 83 and bound proteins complex 
required quite harsh conditions. That the complex survives suggests that the HIF2a 
inhibitors form a strong bond with their target proteins. These findings do not exclude the 
possibility that the compounds form weaker bonds with other proteins that may be 
important in regulation of HIF2a translation. Such targets will be missed in our current 
approach to identify direct targets and should be investigated in future experiments. 
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4.2.2 Development and optimization of pull-down techniques to purify candidate 
proteins 
A possible way to analyze proteins interacting with Compound 83 in a non-covalent way 
might be to click compound 83 to azide coated beads. The interacting proteins would then 
be bound to the beads via compound 83 as well. After separating the beads from the whole 
cell lysates, protein precipitation would then only separate the bound proteins while 
compound 83 and all proteins bound in a covalent way would stick to the beads. Analysis of 
the precipitated proteins could then reveal those proteins. 
In order to analyze and identify the proteins that we could visualize in bands and that were 
bound covalently, compound 83 had to be isolated alongside them from the rest of the lysates 
of treated cells. Different approaches can be used to obtain this isolation. 
For the first mass spectrometry analysis, we used beads coated with azide groups and 
performed the click reaction binding compound 83 directly and covalently to those beads. 
We hoped to ensure specificity of the isolation, because the click reaction is very specific. 
The downside of this approach is however that bound proteins can only be analyzed through 
mass spectrometry analysis after on-resin digestion. The click reaction cannot be reversed 
and the covalent bond between the azide groups of the beads and the alkyne groups of 
compounds 83 cannot be broken specifically. This makes it hard to optimize this method, 
also, because the only way to get results is through mass spectrometry analysis, which is a 
complicated technique, susceptible to small impurities. Therefore, identified proteins by mass 
spectrometry analysis cannot be confirmed by another analysis such as western blot using 
this same approach. However, this approach does not necessarily include protein 
precipitation which can allow analyzation of proteins interacting with compound 83 in a non-
covalent way as mentioned above. This approach led to a list of 64 
Another approach to isolating compound 83, was its biotinylation via click reaction following 
isolation using streptavidin coated beads. Using this method makes it easier to work with 
isolated proteins because the streptavidin-biotin interaction can easily be broken by protein 
precipitation and western blot analysis is possible. This gave us the opportunity of optimizing 
and repeating this approach without having to use mass spectrometry analysis to get results. 
However, it includes more steps and therefore holds more possibilities for errors. Using 
streptavidin coated beads, the click reaction is performed prior to isolation in contrast to 
using azide coated beads were the click reaction represents the isolation. One problem with 
this step was the protein precipitation after the click reaction and prior to the isolation 
through streptavidin coated beads that lead to unspecific protein background. Especially for 
identifying unknown proteins it is crucial to work very clean and have a specific procedure. 
However, with this approach further validation and optimization of the method was possible. 
For example, mass spectrometry results can be evaluated by western blot analysis. 
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4.2.3 Identification of candidate proteins that bind small molecule inhibitors 
Using the two different pull-down and purification techniques described above identified  
IRP1 was suggested to be a direct target protein of the compounds by western blot and mass 
spectrometry analysis. Previous studies with compound 76 showed through mobility shift 
assays that compound 76 enhanced the binding of IRP1 to an IRE of the HIF2a mRNA 
(Zimmer et al. 2008). In addition, loss of IRP1 results in a translational derepression of 
HIF2a mRNA (Anderson et al. 2014). Alongside IRP1, other ion sensing proteins (such as 
Staniocalcin-2 and Calpastatin) were detected by mass spectrometry. This led to our 
hypothesis that the compounds might bind to the ion sensing regions of these proteins. This 
would explain a possible way of how the compounds promote IRP1 binding to the IRE of 
HIF2a, possibly by replacing the iron molecule bound transiently in the iron-sulfur cluster 
of IRP1 thus enhancing its binding to mRNA. 
Additionally, peflin was suggested as a direct target of the compounds by western blot 
analysis. peflin negatively regulates the vesicle transport from the endothelial reticulum to 
the Golgi apparatus by building a dimer with the apoptosis linked gene 2 (ALG-2). This 
dimer is disrupted when peflin binds to calcium (Rayl et al. 2016). In keeping with the earlier 
hypothesis, the compounds could interfere with calcium binding to peflin, therefore 
enhancing its negative effect on vesicle transport. Another hypothesis is that the compounds 
inhibit the building of the peflin and ALG-2 dimer, preventing its negative effect on vesicle 
transport. How this could play a role in HIF regulation and tumorigenesis still remains 
unclear. 
Another interesting protein suggested as possible target of compound 83 was tumor 
susceptibility gene 101 (TSG101). Investigations on the role TSG101 plays in cancer 
progression has been controversial. While TSG101 was believed to be a tumor-suppressor 
protein once it was discovered (Li and Cohen 1996), newer studies then revealed oncogenic 
properties of the protein in both prostate and breast cancer cells (Zhu et al. 2004). 
Additionally, upregulation of TSG 101 has been observed in different types of cancers such 
as papillary thyroid carcinoma (Liu et al. 2002), hepatocellular carcinoma (Shao et al. 2015) 
and lung cancer (Liu et al. 2010), to only name a few. Recently, Xu and Zheng (2019) also 
found higher expression levels of TSG101 in RCC. Additionally, they showed that 
downregulation of TSG101 in RCC cell lines A498 and 786-O inhibited cell proliferation 
through cell cycle arrest. If our compounds play a role in these pathways or if there is a 
connection to hypoxia signaling still remains unknown. 
In conclusion my work led to the identification of candidate proteins targeted by the HIF2a 
inhibitors. Further work is needed to validate these proteins as the direct targets and to 
functionally link them to HIF2a translation and/or hypoxia sensing. There are different 
approaches to further validate candidate target proteins. One approach would be to reverse 
the isolation process. Compound 83 can be biotinylated again by click reaction after cell lysis 
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of treated cells. Then, instead of targeting compound 83 for isolation, indicated target 
proteins can be isolated using immunoprecipitation. Western blot analysis could then again 
be stained with streptavidin HRP to see if the biotinylated compounds were isolated 
alongside the target protein. This would be another prove of the interaction of compound 
83 with these proteins. Another possibility to see that the compounds’ function depends on 
these proteins would be to knock them out and see if the compounds then lose their function 
of reducing HIF translation. Overall, my work lays the ground for using chemical biology to 
discover the mechanism(s) by which protein-targets of the compound regulate hypoxia 
signaling. 
The work presented in this thesis is part of a larger team effort of the Iliopoulos lab and 
partner labs. Of course, planning all of the experiments was done with the help of Othon 
Iliopoulos and all other lab members. Meike Schneider taught me all the main procedures in 
the lab during the first month of my stay. All mass spectrometry analyses were done by other 
labs, as indicated in the methods section. 
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5 Summary 
Some familial cancer syndromes are known to cause renal cell carcinoma (RCC) in afflicted 
subjects. I studied the role of tumor suppressor genes in two syndromes: Birt-Hogg-Dubé 
(BHD) and von Hippel-Lindau (VHL). BHD is caused by a germline mutation of the tumor 
suppressor gene folliculin (FLCN). Patients are at risk of developing RCC throughout their 
lifetime. 
In order to functionally classify the FLCN germ line mutations encountered during genetic 
testing, we established an in vivo assay, based on a mouse xenograft model. In this model, 
reintroduction of wildtype FLCN into FLCN-/- cells, when implanted into 
immunocompromised mice, showed a significant reduction of tumor growth compared to a 
comparable transfection of a non-functional exon 5 deletion. This particular FLCN deletion 
(FLCN p.Gly84_Glu132del) has been detected in a 14 year old patient with RCC of the left 
kidney. 
Germ line mutations in the tumor suppressor von Hippel-Lindau (VHL) gene cause VHL 
disease, which can lead to the development of clear cell RCC. VHL is also mutated 
autosomal in the majority of sporadic clear cell RCC. Binding of the VHL protein to hypoxia 
inducible factors (HIF) leads to their degradation and subsequent suppression of tumor 
growth. Downregulation of the HIF2a subunit is necessary and sufficient for tumor growth 
suppression and thus a promising target for cancer therapy. 
Small molecules inhibiting translation of HIF2a as chemical biology probes were used to 
identify proteins that regulate HIF expression and therefore may be involved in initiation 
and/or progression of RCC. We chemically modified the compounds to track their 
interaction with cellular protein-targets by incorporating an alkyne group in its structure. This 
compound (83), because of the alkyne group, can be isolated or marked with azide containing 
probes via click chemistry. 
Compound 83 can be biotinylated with biotin-azide through a click reaction after cell lysis 
of treated VHL-/- cells. Proteins in these cell lysates bound in a strong way to compound 83 
can be western blotted and made visible using streptavidin. This method showed a specific 
reproducible pattern of protein bands and ensured specificity. Using click chemistry, we 
performed two different isolation methods to later identify candidate proteins through mass 
spectrometry analysis. Among others, iron regulatory protein 1, peflin and Tumor 
susceptibility gene 101 were indicated as the most promising candidate target proteins by 
these methods. However, further experiments will have to be performed in order to evaluate 
these results. 
Both FLCN and VHL play an important role in the development of renal cell carcinoma. 
The results presented here offer an assay to test FLCN mutations seen in BHD patients. 
Also, they give new insights into investigation of hypoxia signaling and its role in RCC. 
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